Manchester scientists have genetically mapped the cancer of a leukaemia patient whose disease was resistant to treatment in order to identify a method of personalising therapy for individuals.
Jul 14, 2015
0
13
Metabolism experts are increasingly convinced that obesity and many of the pathogenic changes it entails, such as Metabolic Syndrome and type 2 diabetes, are a result of chronic inflammatory processes in fatty (adipose) tissue. ...
Jun 8, 2015
0
5
Lung cancer is the leading cause of cancer death worldwide, responsible for some 1.59 million deaths a year. That figure is due, in part, to the fact that the cancer often returns after what, at first, seems to be successful ...
Jun 3, 2015
0
20
A*STAR researchers have clarified the role of one particular regulatory protein in controlling the development of plasma cells, opening up several new avenues toward clinical applications.
Apr 30, 2015
0
3
Hyperactivity and social abnormalities are defining characteristics of ADHD and autism, two developmental disorders that parents and scientists around the world are struggling to understand. At the RIKEN Brain Science Institute ...
Apr 13, 2015
0
44
The most recent results from a clinical trial show that ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continued to control the rare blood cancer, with 95 percent of patients surviving for two years, ...
Apr 9, 2015
0
7
A new study led by researchers at Sweden's Karolinska Institutet and Nanyang Technological University in Singapore, provides experimental evidence that a drug that inhibits the EphB-signaling pathway in the cell effectively ...
Apr 1, 2015
1
67
A new study of acute lymphoblastic leukemia (ALL) led by UC San Francisco researchers puts an intriguing new twist on anti-cancer strategies. Rather than inhibiting cellular signals that arise from a cancer-driving gene—the ...
Mar 26, 2015
0
28
Manchester scientists have a developed a new method to monitor the effect of anti-cancer drugs on very rare leukaemia stem cells. The approach potentially allows doctors to screen patients and personalise their treatment.
Feb 27, 2015
0
34
Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent (sunitinib) or Nexavar (sorafenib) among patients with locally advanced renal cell carcinoma ...
Feb 24, 2015
0
9
